Enzymatica AB (FRA:EN9) Interest Expense: €-0.10 Mil (TTM As of Mar. 2026)

What is Enzymatica AB Interest Expense?

Enzymatica AB FRA:EN9 +4.55% 36 Interest Expense is €-0.10 Mil as of Mar. 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 36/100 and a GF Value™ of €0.16 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Enzymatica AB's interest expense for the three months ended in Mar. 2026 was € -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Enzymatica AB's Operating Income for the three months ended in Mar. 2026 was € -1.26 Mil. Enzymatica AB's Interest Expense for the three months ended in Mar. 2026 was € -0.01 Mil. Enzymatica AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enzymatica AB (FRA:EN9) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enzymatica AB's Interest Expense for the three months ended in Mar. 2026 was €-0.01 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-1.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.00 Mil.

Enzymatica AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Enzymatica AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Enzymatica AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Interest Expense can be seen below:

Enzymatica AB Interest Expense Chart

Enzymatica AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.09

-0.19

-0.15

-0.01

Enzymatica AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-0.05	-0.01	-0.01	-0.07	-0.01

36GF Score

Enzymatica AB FRA:EN9

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Enzymatica AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.10 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-0.10 Mil mean?

Enzymatica AB (FRA:EN9) has a Interest Expense of €-0.10 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Enzymatica AB and its competitors.

Is Enzymatica AB's Interest Expense too high?

Enzymatica AB's current Interest Expense is €-0.10 Mil. Overall, Enzymatica AB has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Enzymatica AB's Interest Expense compare to ZTS and UTHR?

Enzymatica AB's Interest Expense of €-0.10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Drug Manufacturers company?

A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current Interest Expense is €-0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Enzymatica AB stock overvalued right now?

Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.16, compared to a current price of €0.20 — trading 22.2% above its estimated fair value. The current Interest Expense is €-0.10 Mil. Enzymatica AB's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Interest Expense is €-0.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.20 is trading 22.2% above its estimated GF Value™ of €0.16. GuruFocus considers Enzymatica AB to be Modestly Overvalued.

Key valuation signals for FRA:EN9:

Interest Expense: €-0.10 Mil
GF Value™: €0.16 vs. price of €0.20 (22.2% above fair value)
GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies OSTO:NANEXA OSTO:EQL OSTO:CINPHA OSTO:DICOT OSTO:MOB OSTO:ORX OSTO:KLAR XSAT:ACUC OSTO:VIVE OSTO:NEWBRY XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges ENZY:Sweden

Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70

Website http://www.enzymatica.se

Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

36GF Score

Get the complete analysis for FRA:EN9

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20

Price

€0.16

GF Value

View FRA:EN9 Analysis

See Interest Expense data for all stocks →